Day: July 28, 2023

Posted on

CBL International Limited – Chart the Path Towards a Brighter Future

HONG KONG, July 28, 2023 (GLOBE NEWSWIRE) — CBL International Limited (Nasdaq: BANL) are thrilled to share with you a few milestones we have reached since the beginning of this year, which not only demonstrated CBL’s ability to ramp up its capacity but also our commitments to the sustainable development.

In the second quarter of 2023, we further extended our footholds in Antwerp in Belgium, Istanbul in Turkey, and Yokkaichi in Japan. This strategic move brings CBL’s services to over 40 ports and opens up the European market, providing flexibility to our customers.

This is in line with our expansion plan, as outlined in the prospectus, which aims to increase our presence in the international markets with the objective of maximizing our scale of operations and profitability.

Our accomplishments also include notable sustainable initiatives. In the third quarter of 2023, we collaborated with our business partners to deliver our very first B24 biofuel bunkering order in Hong Kong. This was a significant step towards achieving the 2023 IMO Strategy, which was adopted at the Maritime Environment Protection (MEPC 80) conference.

Chairman and CEO, Mr William Chia said, “We take immense pride in our unwavering commitment to environmental sustainability and our efforts to make a positive impact on the shipping industry in Hong Kong. As part of our ESG initiatives, we are steadfastly devoted to reducing greenhouse gas (GHG) emissions in line with the IMO’s targets and have implemented in-house GHG management measures.” To further promote clean energy technology, CBL has obtained ISCC EU and ISCC Plus certificates from Bureau Veritas, which certify its compliance with all necessary requirements and authorize the company to trade biofuel within the supply chain.

Through these efforts, we pledge a continued commitment to promoting sustainable practices within the marine industry as a key player in the sector. We are confident that our progress thus far will continue to bring positive change and yield benefits to our company, our stakeholders, and the environment.

About CBL International Limited

Established in 2015, CBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, an established marine fuel logistic company in Asia Pacific providing customers with one stop solution for vessel refuelling. The main market of Banle Group is the Asia Pacific market with business activities taking place in the major ports of Japan, Korea, China, Hong Kong, Taiwan, Vietnam, Malaysia, Singapore, Thailand, and other countries like Turkey, Belgium.

Forward-Looking Information and Statements

Certain statements in this announcement are forward-looking statements, by their nature, subject to significant risks and uncertainties. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that the offering will be successfully completed. Investors can identify these forward-looking statements by words or phrases such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

CBL INTERNATIONAL LIMITED
(Incorporated in Cayman Islands with limited liabilities)

For more information, please contact:

CBL International Limited

Email: investors@banle-intl.com

GlobeNewswire Distribution ID 8882998

Posted on

LambdaTest announces the integration of its real devices platform with its test orchestration platform HyperExecute to enable blazing-fast mobile testing

Real Device Integration with HyperExecute allows businesses to seamlessly orchestrate and execute test scripts on a diverse range of real devices

San Francisco , July 28, 2023 (GLOBE NEWSWIRE) — LambdaTest, a  leading cloud-based unified testing platform announced the launch of Real Device integration with HyperExecute, a continuous testing cloud solution that enables developers and test engineers to orchestrate and execute tests up to 70% faster.

With the exponential growth of mobile devices and the increasing diversity of smartphones in the market, ensuring a seamless user experience across different mobile devices is vital for businesses to maintain user satisfaction, protect their brand reputation, improve conversion rates, allocate resources effectively, and expand their market reach. The availability of devices, rising costs, and speed constraints have often hindered comprehensive mobile app testing. By addressing the challenges posed by the diverse mobile device landscape, businesses can stay competitive in the digital marketplace and provide a positive and consistent user experience.

LambdaTest addresses this with Real Device Integration on HyperExecute, allowing businesses to test their applications on a wide range of real devices with unparalleled speed and cost-effectiveness. This ensures flawless performance across various screen sizes, operating systems, and hardware configurations, ultimately leading to improved customer satisfaction and a boost in the app’s reputation. HyperExecute offers flexibility by allowing tests to be triggered through the local machine while prioritizing data security, and its integration with Jenkins, a CI/CD automation tool, enables faster real-device testing in automated pipelines.

“LambdaTest’s vision is to empower businesses with cutting-edge solutions that enable them to deliver seamless experiences to their customers. ” expresses Mayank Bhola, Co-Founder and Head of Product at LambdaTest. “With Real Device Integration, LambdaTest is committed to providing a comprehensive testing platform that unlocks the true power of mobile testing. By leveraging a fleet of real devices, businesses can confidently navigate the diverse mobile landscape and ensure their applications perform flawlessly across a range of devices, meeting the high expectations of their tech-savvy customer base.”

As businesses embrace Real Device Integration with HyperExecute, they can accelerate their time-to-market, enhance the quality of their mobile applications, and drive unparalleled customer satisfaction. With LambdaTest as their trusted partner, businesses can stay ahead in the competitive digital marketplace, providing exceptional experiences on a wide range of mobile devices. To know more about real device integration with HyperExecute, visit: https://www.lambdatest.com/support/docs/real-devices-integration-with-hyperexecute/

About LambdaTest
LambdaTest is an intelligent and omnichannel enterprise execution environment that helps businesses drastically reduce time to market through Just in Time Test Orchestration (JITTO),  ensuring quality releases and accelerated digital transformation. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.

● Browser & App Testing Cloud allows users to run both manual and automated tests of web and mobile apps across 3000+ different browsers, real devices, and operating system environments.

● HyperExecute helps customers run and orchestrate test grids in the cloud for any framework and programming language at blazing-fast speeds to cut down on quality test time, helping developers build software faster. For more information, please visit, https://lambdatest.com

LambdaTest press office: press@lambdatest.com

GlobeNewswire Distribution ID 8882656

Posted on

Arbor Metals to Assess Strategic Claims Adjacent to Its Jarnet Lithium Project in Quebec, Canada

Map of Arbor Metal Corp.’s Jarnet Lithium Claims

Arbor’s Jarnet Lithium Mine is located in the James Bay region of Quebec and is comprised of 47 map-designated claims that cover an approximate area of 3,759 hectares.

VANCOUVER, British Columbia, July 28, 2023 (GLOBE NEWSWIRE) — Arbor Metals Corp. (“Arbor” or the “Company”) (TSXV: ABR, FWB: 432) is pleased to announce that the Company has entered into an agreement to grant its technical team access to the data room of a strategically located set of mineral claims adjacent to the Jarnet Lithium Project in the James Bay region of Quebec, Canada. The Company believes that these mineral claims have the potential to augment the scope of the Jarnet Lithium Project significantly, and the technical team is enthusiastic about conducting a comprehensive analysis of all the past exploration information in the data room.

Mark Ferguson, CEO of Arbor, expressed excitement about this new development, stating, “We are thrilled to gain access to the data room, as it allows our technical team to conduct an in-depth examination of all the past exploration data. We believe that this strategic set of claims has the potential to further strengthen our Jarnet project. If our understanding of the claims is confirmed by our analysis, it could enhance Arbor’s position in the lithium market and reinforce our position in the rapidly advancing Canadian EV Industry.”

The agreement will enable Arbor‘s technical team to explore the historical data, geological reports, and exploration results related to the strategic claims. They will evaluate the benefits and possibilities of integrating this proximate project with the Jarnet Lithium Project. Arbor remains committed to driving the exploration and development of the Jarnet project, aiming to capitalize on the increasing global demand for lithium.

Once the technical team completes its thorough data analysis, Arbor will update its shareholders and stakeholders regarding the findings and potential implications for the Jarnet Lithium Project. The Company remains dedicated to transparency and looks forward to sharing the results of this strategic assessment with the investment community.

Arbor is dedicated to responsible resource development and is well-positioned to play a crucial role in supplying the necessary lithium to support the electrification of transportation and the transition to a sustainable future. The Company’s focus on sustainable growth, innovation, and strategic partnerships will continue to drive its efforts in meeting the increasing demand for lithium in Canada’s EV industry.

Dr. Peter Born, P.Geo., is the designated qualified person as defined by National Instrument 43-101 and is responsible for and has approved the technical information in this release.

About Arbor Metals Corp.

Arbor Metals Corp. is a mining exploration company focused on developing high-value, geographically significant mineral projects worldwide. Arbor is paving the way for advanced mineral exploration as it oversees world-class mining projects. The Company is confident that combining quality projects with proven strategies and a dedicated team will yield exceptional outcomes.

The Jarnet lithium project, located in the James Bay region of Quebec, comprises 47 map-designated claims, covering an area of approximately 3,759 hectares. The Jarnet project is contiguous to the Corvette-FCI property, where diamond drilling has confirmed significant lithium mineralization representing one of the highest-profile lithium exploration projects in the sector.

Arbor Map

For further information, contact Mark Ferguson, Chief Executive Officer, at info@arbormetals.com, or 403.852.4869, or visit the Company’s website at www.arbormetalscorp.com.

On behalf of the Board,

Arbor Metals Corp.

Mark Ferguson, Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When or if used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the development of the Jarnet Lithium Project, and the assessment of data from adjacent claims, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance, or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.

CONTACT:

MRKT360 INC
https://mrkt360.com
Alex Zertuche
alexz@mrkt360.com
For E.S.T Office Hours, Call 1 416-477-0587

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1ac9c34f-6084-4782-a8ec-1c2f30b35a1a

GlobeNewswire Distribution ID 8882541

Posted on

AKWEL: HALF-YEAR REVENUE UP +11.8%

        Thursday 27 July 2023

HALF-YEAR REVENUE UP +11.8%

AKWEL (FR0000053027, AKW, PEA-eligible), the automotive and HGV equipment and systems manufacturer specialising in fluid and mechanism management and structural parts for electric vehicles, posted consolidated revenue of €545.8m over the first half of 2023.

Consolidated revenue

In € millions – unaudited 2023 2022 Variation Like-for-like variation (1)
1st quarter 274.6 245.8 +11.7% +14.6%
2nd quarter 271.2 242.3 +11.9% +17.7%
1st half-year 545.8 488.1 +11.8% +16.2%

(1) Comparing like-for-like figures

With the global automotive market once again experiencing growth, AKWEL recorded an 11.9% increase in reported revenue in the second quarter of 2023 and a 17.7% increase comparing like-for-like figures. The Group posted a fifth consecutive quarter of double-digit growth.

Products and Functions revenue was up by 11.8% to €529.3m. The Washer Systems (+22.0%), Mechanisms (+18.0%) and Cooling (+15.5%) businesses were the most dynamic over the period, and Electric Vehicle Structural Parts (+85%) continued to ramp. Meanwhile, Tooling revenue increased by 16.4% to €12.8m.

The consolidated net cash position excluding lease obligations and after the dividend payout progressed to €101.1m at 30 June 2023, with €23.8m in investments made over the half-year period.

Given the performance achieved in the first half of the year and the more favourable business outlook for the automotive and HGV sector worldwide, AKWEL confirms that it expects around 10% revenue growth in the 2023 financial year.

In connection with the implementation of the share buyback programme, authorised by the General Meeting of 25 May 2023, AKWEL signed a share buyback agreement. This takes effect today and will cover a maximum of €133.4 million. The purpose of the programme is to cancel the shares thus redeemed, under the conditions provided for by law.

An independent, family-owned group listed on the Euronext Paris Stock Exchange, AKWEL is an automotive and HGV equipment and systems manufacturer specialising in fluid management, mechanisms and structural components for electric vehicles. The Group achieves this by relying on state-of-the-art industrial and technological expertise in applying and processing materials (plastics, rubber, metal) and mechatronic integration.

Operating in 21 countries across every continent, AKWEL employs 9,500 people worldwide.

Attachment

GlobeNewswire Distribution ID 1000831885

Posted on

Omico Brings Cutting Edge Technology Earlier in the Clinical Research Process

Omico Will Precisely Match Patients to George Clinical Oncology Trials

SYDNEY, July 27, 2023 (GLOBE NEWSWIRE) — George Clinical recognises and applauds its collaborative partner Omico, with whom it is aligned in a common goal to revolutionize oncology clinical trial access for patients and improve the efficiency of study enrollment, on the launch of their landmark program PrOSPeCT–a program that brings precision oncology trials to the Australian community by linking genomic technology to trials of new therapeutic products.

Omico is an Australian government-backed national network of leading researchers, clinicians and industry partners, including George Clinical, that are using precision medicine to unlock new potential in Australian research and turn the tide on cancer. With fast-tracked molecular screening, biomarker-led trial set up and patient enrolment across the entire nation, Omico is accelerating access to next-generation treatments and preventive strategies improving outcomes for all Australians affected by cancer.

“Omico provides a faster, better way to perform cancer molecular screening, enroll patients and set up biomarker-led clinical trials thereby offering George Clinical, our sponsor partners, sites, and patients, the ability to match genetically eligible patients to cutting edge oncology clinical trials being conducted in Australia in a non-traditional, more efficient and direct model,” said Susan Cole, global head therapeutic strategy, oncology for George Clinical.

Through the PrOSPeCT initiative, Omico is further expanding its reach by opening up new treatment paths across Australia for people with difficult-to-treat cancers including those with ovarian cancers, pancreatic cancers, sarcomas, and advanced and metastatic cancers. PrOSPeCT has three main aims: to screen a magnitude of patients that is beneficial to the Australian public and the economy with 23,000 patients to access free, cutting edge genomic screening; to match patients to precision medicines in clinical trials that are being conducted across Australia; and to create a database of real-world data that will be useful in the future for further research.

”Omico is committed to supporting the Australian life sciences industry. It is through organizations like George Clinical that we support more clinical trials in Australia, creating new jobs, while bringing hope to our patients battling cancer”, says Professor David Thomas, oncologist, founder and CEO of Omico.

George Clinical’s success with oncology trials has been driven by scientific expertise and operational excellence. The synergy between the two organizations is no better demonstrated than the current collaboration undertaking early phase molecular screening dependent trials in Australia that require the ability to combine the targeted identification of patients through the use of the Omico’s PrOSPeCT initiative to accelerate access to precision oncology, and George Clinical’s focus on the scientific objective leading to success through maximizing site selection, recruitment, and overall trial efficiencies for the best result possible.

About George Clinical
George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With over 20 years of experience and more than 500 people managing over 39 geographical locations throughout the Asia-Pacific region, USA, and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration and post-marketing trials.   

Matthew Reabold
George Clinical
760-645-0496
mreabold@georgeclinical.com

GlobeNewswire Distribution ID 8882275

Posted on

Publication Relating to a Transparency Notification

REGULATED INFORMATION

Publication Relating to a Transparency Notification

Mont-Saint-Guibert (Belgium), July 27, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a rectification of an earlier transparency notification.

On July 25, 2023, Nyxoah received the rectification of the April 16, 2023 transparency notification that it had received from ResMed Inc. in relation to the upward crossing of the 5% threshold by ResMed Inc. on March 30, 2023. The correction relates to the number of shares and the percentage of voting rights held by ResMed Inc. on March 30, 2023: ResMed Inc. held 1,619,756 shares, representing 5.73% of the total number of voting rights (and not 1,499,756 shares or 5.30% of the voting rights as stated in the April 2023 notification).

The notification dated July 17, 2023 contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: a person that notifies alone
  • Persons subject to the notification requirement: ResMed Inc., 9001 Spectrum Center Boulevard, San Diego, CA 92123, USA
  • Date on which the threshold was crossed: March 30, 2023
  • Threshold that is crossed: 5%
  • Denominator: 28,286,985
  • Notified details:
A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the
securities		 Linked to securities Not linked to the
securities
ResMed Inc. 794,235 1,619,756 5.73%
TOTAL 1,619,756 0 5.73% 0.00%
  • Chain of controlled undertakings through which the holding is effectively held: No indirect holding of voting securities. ResMed Inc. is not a controlled entity.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

GlobeNewswire Distribution ID 1000831958

Posted on

Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023

Mont-Saint-Guibert, Belgium – July 27, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter of 2023 on Tuesday, August 8, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah’s Q2 2023 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: Nyxoah’s Q2 2023 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment

GlobeNewswire Distribution ID 1000831970